Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19185810 | 0.85 | L3MBTL1 (1.00) | L3MBTL1HTTMAPTPOLBMAPK1 | |
| SCHEMBL3880219 | 0.82 | L3MBTL1 (0.50) | L3MBTL1MAPTKDM4EIP6K1BRAF | |
| SCHEMBL27174580 | 0.81 | L3MBTL1 (0.54) | L3MBTL1HTTMAPTKDM4EIP6K1 | |
| SCHEMBL29539639 | 0.81 | L3MBTL1 (0.54) | L3MBTL1HTTMAPTKDM4EIP6K1 | |
| SCHEMBL24569513 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HTTMAPTKDM4ELMNA | |
| SCHEMBL9922441 | 0.77 | KDM4E (0.58) | L3MBTL1MAPK1KDM4EIP6K1BRAF | |
| SCHEMBL30648059 | 0.77 | KDM4E (0.58) | L3MBTL1MAPK1KDM4EIP6K1BRAF | |
| SCHEMBL4266168 | 0.76 | MAPT (0.48) | L3MBTL1HTTMAPTPOLBMAPK1 | |
| SCHEMBL9800651 | 0.75 | HTT (0.49) | L3MBTL1HTTMAPTMAPK1KDM4E | |
| SCHEMBL4042675 | 0.75 | L3MBTL1 (0.43) | L3MBTL1HTTMAPTPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010504-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119055-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BRAF, RAF1, NRAS | L3MBTL1 4021/4885HTT 4309/4885MAPT 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.